T1	SectionAnnotate 195 222	HISTORY OF PRESENT ILLNESS:
T2	SectionAnnotate 2975 2992	Review of Systems
T4	SectionAnnotate 3934 3955	Past Medical History:
T5	SectionAnnotate 4294 4316	Past Surgical History:
T6	SectionSkip 4896 6560	Current Medications       Dosage    albuterol 90 mcg/actuation metered dose inhaler Inhale 1-2 puffs into the lungs every 6 (six) hours as needed.     cetirizine (ZYRTEC) 10 mg tablet Take 10 mg by mouth daily as needed.     diphenoxylate-atropine (LOMOTIL) 2.5-0.025 mg tablet Take 2 tabs after each loose bowel movement. You can take up to 8 tabs a day. FOR DIARRHEA.    fluticasone propion-salmeterol (ADVAIR DISKUS) 100-50 mcg/dose diskus inhaler Inhale 1 puff into the lungs Twice a day.    lipase-protease-amylase (CREON) 24,000-76,000 -120,000 unit CAPDREC capsule take 3-4 caps with each meal and April 23 caps with each snack.    LORazepam (ATIVAN) 1 mg tablet Take 1 tablet (1 mg total) by mouth every 8 (eight) hours as needed (nausea/vomiting).    metoclopramide HCl (REGLAN) 10 mg tablet Take 1 tab 30 minutes prior to every meal. Take 3 times a day. For NAUSEA.    mirtazapine (REMERON) 15 mg tablet Take 1 tablet (15 mg total) by mouth nightly at bedtime.    OLANZapine (ZYPREXA) 5 mg tablet Take 1 or 2 tabs on the 
 day of chemotherapy followed by 1 or 2 tabs once daily for 3 days following chemotherapy infusion. FOR NAUSEA.    olopatadine (PATANOL) 0.1 % ophthalmic solution Apply 1 drop to eye.    oxyCODONE (ROXICODONE) 5 mg tablet Take 1-2 tablets (5-10 mg total) by mouth every 4 (four) hours as needed for Pain.    ranitidine (ZANTAC) 150 mg tablet Take 150 mg by mouth Twice a day.    TRIAMCINOLONE ACETONIDE (NASACORT NASAL) by Nasal route daily as needed.       Hospital Medications       Dosage    heparin flush 100 unit/mL injection syringe 500 Units Inject 5 mLs (500 Units total) into the vein As needed (line flush after each use).
T7	SectionAnnotate 6767 6781	Family History
T8	SectionAnnotate 7222 7236	Social History
T9	SectionAnnotate 7991 8015	Social History Narrative
T10	SectionSkip 8039 8243	OBJECTIVE ASSESSMENT  BP 105/59  | Pulse 80  | Temp 36.8 C (98.2 F) (Oral)  | Resp 18  | Ht 154.9 cm (5' 0.98") Comment: April 2018 | Wt 53.9 kg (118 lb 14.4 oz)  | SpO2 100%  | BMI 22.48 kg/m     ECOG: 1
T11	SectionSkip 8247 9317	Physical Exam   Nursing note and vitals reviewed.  Constitutional: She is oriented to person, place, and time. She appears well-developed and well-nourished.   HENT:   Head: Normocephalic.   Right Ear: External ear normal.   Left Ear: External ear normal.   Eyes: Pupils are equal, round, and reactive to light. EOM are normal. No scleral icterus.   Neck: Neck supple. No tracheal deviation present. No thyromegaly present.   Cardiovascular: Normal rate, regular rhythm and intact distal pulses. Exam reveals no friction rub.   Pulmonary/Chest: Breath sounds normal. No respiratory distress. She exhibits no tenderness.   Abdominal: Soft. Bowel sounds are normal. There is no tenderness. There is no rebound.   Musculoskeletal: Normal range of motion. She exhibits no edema, tenderness or deformity.   Neurological: She is alert and oriented to person, place, and time. No cranial nerve deficit. She exhibits normal muscle tone.   Skin: Skin is warm and dry. No rash noted.   Psychiatric: She has a normal mood and affect. Her behavior is normal. Thought content normal.
T13	SectionSkip 9322 10621	LABORATORY RESULTS  I have reviewed the following labs in clinic today and discussed them with the patient.  Lab Results   Component Value Date    WBC Count 5.3 08/12/2018    Neutrophil Absolute Count 3.56 08/12/2018    Hemoglobin 10.1 (L) 08/12/2018    Hematocrit 32.1 (L) 08/12/2018    Platelet Count 159 08/12/2018     Lab Results   Component Value Date    Creatinine 0.51 08/12/2018    Sodium, Serum / Plasma 136 07/29/2018    Potassium, Serum / Plasma 4.2 07/29/2018    Calcium, total, Serum / Plasma 
 8.3 (L) 07/29/2018     Lab Results   Component Value Date    Bilirubin, Total 0.4 08/12/2018    Alkaline Phosphatase 61 08/12/2018    Aspartate transaminase 28 08/12/2018    Alanine transaminase 25 08/12/2018    Albumin, Serum / Plasma 3.1 (L) 07/29/2018    Int'l Normaliz Ratio 1.1 02/28/2018     Lab Results   Component Value Date    Cancer Antigen 19-9 1,109 (H) 07/15/2018    Cancer Antigen 19-9 2,762 (H) 06/17/2018    Cancer Antigen 19-9 3,525 (H) 05/20/2018    Carcinoembryonic Antigen 3.0 08/04/2015    Carcinoembryonic Antigen 2.7 06/07/2015    Carcinoembryonic Antigen 2.5 04/04/2015     Molecular: BRCA variant of unknown significance in the setting of a family history of cancer and a personal history of breast and pancreatic cancer.  K-ras and CDKN2a and APC mutations as well.
T14	SectionSkip 9644 9848	Lab Results   Component Value Date    Creatinine 0.51 08/12/2018    Sodium, Serum / Plasma 136 07/29/2018    Potassium, Serum / Plasma 4.2 07/29/2018    Calcium, total, Serum / Plasma 
 8.3 (L) 07/29/2018
T17	SectionAnnotate 11072 11083	Impression:
T18	ClinicalCondition 67 84	Pancreatic Cancer
T19	PROBLEM 123 151	metastatic pancreatic cancer
T20	PROBLEM 153 161	BRCA VUS
T21	PROBLEM 163 187	Lung predominant disease
T22	TEST 262 272	evaluation
T23	PROBLEM 276 308	her metastatic pancreatic cancer
T24	TREATMENT 353 371	1st line treatment
T25	TREATMENT 377 387	FOLFIRINOX
T26	TREATMENT 460 474	10 cycles- XRT
T27	ClinicalCondition 497 500	SLE
T28	TREATMENT 538 548	FOLFIRINOX
T29	PROBLEM 555 576	peripheral neuropathy
T30	TREATMENT 594 624	treatment    2ndline treatment
T31	TREATMENT 626 644	PD in lungs biopsy
T32	TREATMENT 653 678	5FU &liposomal irinotecan
T33	TREATMENT 764 784	olanzapine (Zyprexa)
T34	TREATMENT 852 855	5FU
T35	TREATMENT 857 877	liposomal irinotecan
T36	Radiology 889 893	Scan
T37	PROBLEM 901 927	slight increase in primary
T38	TEST 933 935	CA
T39	TREATMENT 968 975	C19 5FU
T40	TREATMENT 977 997	liposomal irinotecan
T41	TREATMENT 1012 1037	5FU +liposomal irinotecan
T42	TREATMENT 1066 1069	5FU
T43	ClinicalCondition 1078 1089	neutropenia
T44	TEST 1134 1141	CT scan
T45	PROBLEM 1149 1182	interval progression in the lungs
T46	PROBLEM 1191 1211	disease in the liver
T47	TREATMENT 1233 1258	5FU +liposomal irinotecan
T48	TEST 1272 1274	CT
T49	PROBLEM 1282 1308	essentially stable disease
T50	TREATMENT 1338 1378	a catheter-related clot in the right SVC
T51	ProcedureName 1392 1432	IR removal of indwelling venous catheter
T52	TREATMENT 1438 1474	placement of midline venous catheter
T53	TREATMENT 1497 1522	5FU +liposomal irinotecan
T54	TREATMENT 1565 1598	single-agent liposomal irinotecan
T55	TREATMENT 1610 1652	Cycle 35 single-agent liposomal irinotecan
T56	TEST 1666 1668	CT
T57	PROBLEM 1676 1690	stable disease
T58	DiagnosticLabTest 1701 1714	tumor markers
T59	PROBLEM 1766 1777	symptomatic
T60	PROBLEM 1783 1797	ongoing nausea
T61	PROBLEM 1798 1806	vomiting
T62	PROBLEM 1833 1852	disease progression
T63	TREATMENT 1854 1874	Liposomal irinotecan
T64	PROBLEM 2007 2021	the BRCA2 gene
T65	TREATMENT 2105 2119	nab-paclitaxel
T66	ClinicalCondition 2223 2241	hyperbilirubinemia
T67	PROBLEM 2246 2272	gastric outlet obstruction
T68	TEST 2274 2278	ERCP
T69	ClinicalCondition 2300 2334	high grade post-bulbar obstruction
T70	TREATMENT 2357 2370	the endoscope
T71	ProcedureName 2375 2388	the procedure
T72	ProcedureName 2412 2430	uncomplicated PTBD
T73	TREATMENT 2463 2479	a duodenal stent
T74	TREATMENT 2614 2625	Gemcitabine
T75	TREATMENT 2628 2636	Abraxane
T76	TREATMENT 2656 2667	Gemcitabine
T77	TREATMENT 2670 2678	Abraxane
T78	TREATMENT 2697 2708	Gemcitabine
T79	TREATMENT 2711 2719	Abraxane
T80	TREATMENT 2739 2750	Gemcitabine
T81	TREATMENT 2753 2761	Abraxane
T82	TREATMENT 2780 2791	Gemcitabine
T83	TREATMENT 2794 2802	Abraxane
T84	TREATMENT 2822 2833	Gemcitabine
T85	TREATMENT 2836 2844	Abraxane
T86	TREATMENT 2862 2873	Gemcitabine
T87	TREATMENT 2876 2884	Abraxane
T88	PROBLEM 2907 2927	Worsening neuropathy
T89	PROBLEM 2930 2947	Improved abd pain
T90	PROBLEM 2951 2967	Trouble sleeping
T91	PROBLEM 3024 3030	chills
T92	PROBLEM 3032 3043	diaphoresis
T93	PROBLEM 3045 3050	fever
T94	PROBLEM 3052 3059	malaise
T95	PROBLEM 3060 3067	fatigue
T96	PROBLEM 3072 3083	weight loss
T97	PROBLEM 3106 3116	nosebleeds
T98	Symptom 3177 3182	cough
T99	Symptom 3184 3194	hemoptysis
T100	Symptom 3199 3218	shortness of breath
T101	Symptom 3252 3262	chest pain
T102	Symptom 3267 3279	leg swelling
T103	Symptom 3314 3328	abdominal pain
T104	Symptom 3343 3355	constipation
T105	Symptom 3357 3365	diarrhea
T106	Symptom 3367 3373	nausea
T107	Symptom 3378 3386	vomiting
T108	Symptom 3418 3428	flank pain
T109	Symptom 3433 3440	urgency
T110	Symptom 3474 3479	falls
T111	Symptom 3481 3491	joint pain
T112	Symptom 3496 3505	neck pain
T113	Symptom 3539 3546	itching
T114	Symptom 3577 3591	sensory change
T115	Symptom 3606 3615	dizziness
T116	Symptom 3617 3624	tremors
T117	Symptom 3626 3639	speech change
T118	Symptom 3641 3655	focal weakness
T119	Symptom 3660 3681	loss of consciousness
T120	Symptom 3756 3766	depression
T121	Symptom 3768 3779	memory loss
T122	Symptom 3847 3854	anxious
T123	Symptom 3873 3881	insomnia
T124	TEST 3886 3903	All other systems
T125	ClinicalCondition 3979 3985	Asthma
T126	ClinicalCondition 3991 4010	Breast cancer (HCC)
T127	ProcedureName 4016 4036	Difficult intubation
T128	TREATMENT 4091 4117	easy intubation Glidescope
T129	TREATMENT 4119 4144	Glidescope LoPro T4 vs T3
T130	ProcedureName 4175 4210	continuous positive airway pressure
T131	ProcedureName 4212 4225	CPAP) therapy
T132	ClinicalCondition 4231 4236	Lupus
T133	Symptom 4242 4248	Nausea
T134	ClinicalCondition 4264 4287	Obstructive sleep apnea
T135	TREATMENT 4319 4366	Procedure Laterality Date    BREAST LUMPECTOMY
T136	ProcedureName 4386 4406	Chest port placement
T137	ProcedureName 4434 4437;4443 4461	EGD PEG/TUBE PLACEMENT
T138	TREATMENT 4443 4461	PEG/TUBE PLACEMENT
T139	TREATMENT 4478 4515	IR PERCUTANEOUS CHOLECYSTOSTOMY DRAIN
T140	ProcedureName 4554 4591	IR PERCUTANEOUS CHOLECYSTOSTOMY DRAIN
T141	ProcedureName 4664 4681	IR PORT PLACEMENT
T142	ProcedureName 4739 4756	IR PORT PLACEMENT
T143	TEST 4852 4863	LUNG BIOPSY
T144	ProcedureName 4874 4888	TUBAL LIGATION
T145	TREATMENT 4904 4915	Medications
T146	TREATMENT 4922 4941	Dosage    albuterol
T147	MedicationName 5047 5066	cetirizine (ZYRTEC)
T148	MedicationName 5121 5153	diphenoxylate-atropine (LOMOTIL)
T149	PROBLEM 5256 5264	DIARRHEA
T150	MedicationName 5269 5315	fluticasone propion-salmeterol (ADVAIR DISKUS)
T151	MedicationName 5392 5423	lipase-protease-amylase (CREON)
T152	TREATMENT 5460 5467	capsule
T153	MedicationName 5535 5553	LORazepam (ATIVAN)
T154	PROBLEM 5635 5641	nausea
T155	PROBLEM 5642 5650	vomiting
T156	MedicationName 5656 5683	metoclopramide HCl (REGLAN)
T157	Symptom 5764 5770	NAUSEA
T158	MedicationName 5775 5796	mirtazapine (REMERON)
T159	MedicationName 5870 5890	OLANZapine (ZYPREXA)
T160	TREATMENT 5936 5948	chemotherapy
T161	TREATMENT 6005 6026	chemotherapy infusion
T162	PROBLEM 6032 6038	NAUSEA
T163	MedicationName 6043 6064	olopatadine (PATANOL)
T164	MedicationName 6115 6137	oxyCODONE (ROXICODONE)
T165	Symptom 6227 6231	Pain
T166	MedicationName 6236 6255	ranitidine (ZANTAC)
T167	MedicationName 6307 6347	TRIAMCINOLONE ACETONIDE (NASACORT NASAL)
T169	TREATMENT 6532 6543	(line flush
T170	PROBLEM 6569 6578	Allergies
T171	TREATMENT 6599 6617	Allergen Reactions
T172	TREATMENT 6622 6639	Levofloxacin Rash
T173	TREATMENT 6644 6673	Shellfish Containing Products
T174	PROBLEM 6674 6679	Hives
T175	PROBLEM 6684 6691	Itching
T176	TREATMENT 6696 6714	Alendronate Sodium
T177	PROBLEM 6715 6719	Rash
T178	PROBLEM 6724 6740	Anastrozole Rash
T179	PROBLEM 6745 6761	Terbinafine Rash
T180	PROBLEM 6823 6837	Stomach cancer
T181	PROBLEM 6853 6865	Colon cancer
T182	PROBLEM 6881 6894	Rectal cancer
T183	PROBLEM 6910 6923	Breast cancer
T184	PROBLEM 6946 6952	Cancer
T185	PROBLEM 6974 6987	Breast cancer
T186	PROBLEM 7015 7027	Brain cancer
T187	PROBLEM 7070 7083	Breast cancer
T188	PROBLEM 7131 7144	Breast cancer
T189	PROBLEM 7191 7208	Bleeding disorder
T190	TEST 8049 8059	ASSESSMENT
T191	TEST 8061 8063	BP
T192	TEST 8074 8079	Pulse
T193	TEST 8086 8090	Temp
T194	TEST 8096 8097	C
T195	TEST 8117 8121	Resp
T196	TEST 8128 8130	Ht
T197	TEST 8173 8175	Wt
T198	TEST 8204 8208	SpO2
T199	TEST 8217 8220	BMI
T200	TEST 8280 8286	vitals
T201	PROBLEM 8578 8593	scleral icterus
T202	PROBLEM 8619 8637	tracheal deviation
T203	PROBLEM 8650 8661	thyromegaly
T204	TEST 8743 8747	Exam
T205	PROBLEM 8759 8771	friction rub
T206	TEST 8792 8805	Breath sounds
T207	PROBLEM 8817 8837	respiratory distress
T208	PROBLEM 8855 8865	tenderness
T209	PROBLEM 8923 8933	tenderness
T210	PROBLEM 8947 8954	rebound
T211	PROBLEM 9015 9020	edema
T212	PROBLEM 9022 9032	tenderness
T213	PROBLEM 9036 9045	deformity
T214	PROBLEM 9120 9141	cranial nerve deficit
T215	PROBLEM 9209 9213	rash
T216	TEST 9469 9472	WBC
T217	TEST 9473 9478	Count
T218	TEST 9497 9507	Neutrophil
T219	TEST 9508 9522	Absolute Count
T220	TEST 9542 9552	Hemoglobin
T221	TEST 9559 9560	L
T222	TEST 9576 9586	Hematocrit
T223	TEST 9610 9624	Platelet Count
T224	TEST 9644 9655	Lab Results
T225	TEST 9668 9673	Value
T226	TEST 9682 9692	Creatinine
T227	TEST 9712 9718	Sodium
T228	TEST 9720 9725	Serum
T229	TEST 9728 9734	Plasma
T230	TEST 9753 9762	Potassium
T231	TEST 9764 9769	Serum
T232	TEST 9772 9778	Plasma
T233	TEST 9797 9804	Calcium
T234	TEST 9806 9811	total
T235	TEST 9813 9818	Serum
T236	TEST 9821 9827	Plasma
T237	TEST 9891 9900	Bilirubin
T238	TEST 9902 9907	Total
T239	TEST 9926 9946	Alkaline Phosphatase
T240	TEST 9964 9986	Aspartate transaminase
T241	TEST 10004 10024	Alanine transaminase
T242	TEST 10042 10049	Albumin
T243	TEST 10051 10056	Serum
T244	TEST 10059 10065	Plasma
T245	TEST 10094 10102	Normaliz
T246	TEST 10103 10108	Ratio
T247	TEST 10166 10172	Cancer
T248	TEST 10173 10180	Antigen
T249	TEST 10210 10224	Cancer Antigen
T250	TEST 10254 10268	Cancer Antigen
T251	TEST 10298 10322	Carcinoembryonic Antigen
T252	TEST 10341 10365	Carcinoembryonic Antigen
T253	TEST 10384 10408	Carcinoembryonic Antigen
T254	PROBLEM 10439 10451	BRCA variant
T255	ClinicalCondition 10514 10520	cancer
T256	PROBLEM 10547 10575	breast and pancreatic cancer
T257	GenomicTest 10578 10583	K-ras
T258	PROBLEM 10588 10594	CDKN2a
T259	PROBLEM 10599 10612	APC mutations
T260	TEST 10649 10651	CT
T261	TEST 10652 10668	Chest abd pelvis
T262	PROBLEM 10711 10738	bilateral pulmonary nodules
T263	PROBLEM 10755 10773	treated metastases
T264	PROBLEM 10829 10888	hypoattenuating/hypoenhancing proximal pancreatic body mass
T265	PROBLEM 10894 10950	interval decrease in associated infiltrative soft tissue
T266	PROBLEM 10955 10982	significant interval change
T267	PROBLEM 10986 11016	associated vascular encasement
T268	PROBLEM 11021 11030	occlusion
T269	PROBLEM 11104 11133	metastatic pancreatic  cancer
T270	PROBLEM 11168 11196	Metastatic pancreatic cancer
T271	DiseaseState 11230 11244	stable disease
T272	PROBLEM 11249 11259	neuropathy
T273	TREATMENT 11262 11286	Further reduced abraxane
T274	Symptom 11304 11314	neuropathy
T275	Radiology 11331 11338	CT scan
T276	MedicationName 11385 11392	remeron
T277	Symptom 11415 11421	Nausea
T278	Symptom 11422 11430	vomiting
T279	TREATMENT 11434 11445	GOO stented
T280	Symptom 11501 11511	neuropathy
T281	TREATMENT 11765 11785	the treatment 
 plan
T282	TREATMENT 11787 11803	medication risks
T283	TREATMENT 11805 11827	lifestyle modification
T284	PROBLEM 11832 11840	symptoms
A1	ChronicVal T18 non-chronic
A2	ContinuityVal T18 unclear
T285	ClinicalCondition 134 151	pancreatic cancer
A3	ChronicVal T285 non-chronic
A4	ContinuityVal T285 unclear
A5	ExperiencerVal T285 patient
T286	Metastasis 123 133	metastatic
R1	TumorDesc TumorDetails:T286 Desc:T285	
T287	GenomicTestResult 153 161	BRCA VUS
A6	GenomicTestType T287 Unclear
T288	Site 163 167	Lung
R2	SiteOf Arg1:T288 Arg2:T286	
T289	ClinicalCondition 291 308	pancreatic cancer
A7	ChronicVal T289 non-chronic
A8	ContinuityVal T289 unclear
T290	Metastasis 280 290	metastatic
R3	TumorDesc TumorDetails:T290 Desc:T289	
T291	MedicationRegimen 377 387	FOLFIRINOX
A9	TreatmentContinuityVal T291 finished
A10	TreatmentIntentVal T291 palliative
T292	Cycles 426 428	12
T293	Cycles 460 462	10
T294	Cycles 477 478	2
T295	Cycles 520 522	12
T296	Cycles 718 720	12
T297	Cycles 1494 1496	33
T298	Cycles 1616 1618	35
T299	Datetime 832 840	11/15/16
T300	Datetime 879 887	12/31/16
T301	Datetime 956 966	01/23/2017
T302	Datetime 999 1007	02/04/17
T303	Datetime 1040 1048	02/21/17
T304	Datetime 1122 1132	04/30/2017
T305	Datetime 1213 1221	05/14/17
T306	Datetime 1262 1270	10/18/17
T307	Datetime 1382 1390	10/29/17
T308	Datetime 1478 1486	10/29/17
T309	Datetime 1524 1532	11/01/17
T310	Datetime 1600 1608	12/10/17
T311	Datetime 1656 1664	12/18/17
T312	Cycles 1050 1052	21
T313	RadiationTherapyName 471 474	XRT
A11	TreatmentContinuityVal T313 finished
A12	TreatmentTypeVal T313 local
A13	TreatmentIntentVal T313 palliative
R4	TreatmentDesc Therapy:T313 Desc:T294	
R5	TreatmentDesc Therapy:T291 Desc:T292	
R6	TreatmentDesc Therapy:T291 Desc:T293	
T314	MedicationRegimen 538 548	FOLFIRINOX
A14	TreatmentContinuityVal T314 finished
A15	TreatmentIntentVal T314 palliative
T315	MedicationRegimen 653 678	5FU &liposomal irinotecan
A16	TreatmentContinuityVal T315 continuing
A17	TreatmentIntentVal T315 palliative
T316	MedicationRegimen 852 877	5FU +liposomal irinotecan
A18	TreatmentContinuityVal T316 continuing
A19	TreatmentIntentVal T316 palliative
T317	MedicationRegimen 972 997	5FU +liposomal irinotecan
A20	TreatmentContinuityVal T317 continuing
A21	TreatmentIntentVal T317 palliative
T318	MedicationRegimen 1012 1037	5FU +liposomal irinotecan
A22	TreatmentContinuityVal T318 continuing
A23	TreatmentIntentVal T318 palliative
T319	MedicationRegimen 1233 1258	5FU +liposomal irinotecan
A24	TreatmentContinuityVal T319 finished
A25	TreatmentIntentVal T319 palliative
T320	MedicationRegimen 1497 1522	5FU +liposomal irinotecan
A26	TreatmentContinuityVal T320 continuing
A27	TreatmentIntentVal T320 palliative
T321	MedicationName 1066 1069	5FU
A28	TreatmentTypeVal T321 maintenance
A29	TreatmentIntentVal T321 palliative
A30	TreatmentCategory T321 AntiNeoPlastics
T322	MedicationRegimen 1578 1598	liposomal irinotecan
A31	TreatmentContinuityVal T322 continuing
A32	TreatmentIntentVal T322 palliative
T323	MedicationRegimen 1632 1652	liposomal irinotecan
A33	TreatmentContinuityVal T323 continuing
A34	TreatmentIntentVal T323 palliative
A35	ChronicVal T27 chronic
R7	TreatmentDiscontinuedBecauseOf Therapy:T313 Reason:T27	
R8	TreatmentDesc Therapy:T295 Desc:T314	
T324	Symptom 555 576	peripheral neuropathy
A36	IsPresentOnFirstCancerDiagnosis T324 no
A37	IsCausedByDiagnosedCancer T324 no
A38	ChronicVal T324 non-chronic
A39	ContinuityVal T324 improving
R9	ConditionOrTreatmentCausesProblem Treatment:T314 Prob:T324	
T325	DiseaseState 626 628	PD
R10	TreatmentDesc Therapy:T315 Desc:T296	
T326	Symptom 734 735	n
A40	IsPresentOnFirstCancerDiagnosis T326 no
A41	IsCausedByDiagnosedCancer T326 no
A42	ChronicVal T326 non-chronic
A43	ContinuityVal T326 stopped
T327	Symptom 736 737	v
A44	IsPresentOnFirstCancerDiagnosis T327 no
A45	IsCausedByDiagnosedCancer T327 no
A46	ChronicVal T327 non-chronic
A47	ContinuityVal T327 stopped
R11	ConditionOrTreatmentCausesProblem Treatment:T315 Prob:T327	
R12	ConditionOrTreatmentCausesProblem Treatment:T315 Prob:T326	
T328	Cycles 1009 1011	20
T329	Radiology 1134 1141	CT scan
A48	IntentVal T329 TreatmentAssessment
T330	Radiology 1272 1274	CT
A49	IntentVal T330 TreatmentAssessment
T331	Radiology 1666 1668	CT
A50	IntentVal T331 TreatmentAssessment
T332	Cycles 2609 2613	C1D1
T333	Cycles 2692 2696	C2D1
T334	Cycles 2733 2738	C2D15
T335	Cycles 2775 2779	C3D1
T336	Cycles 2816 2821	C3D15
T337	Cycles 2857 2861	C4D1
T338	MedicationRegimen 2614 2636	Gemcitabine + Abraxane
A51	TreatmentContinuityVal T338 continuing
A52	TreatmentTypeVal T338 maintenance
A53	TreatmentIntentVal T338 palliative
T339	MedicationRegimen 2656 2678	Gemcitabine + Abraxane
A54	TreatmentContinuityVal T339 continuing
A55	TreatmentTypeVal T339 maintenance
A56	TreatmentIntentVal T339 palliative
T340	MedicationRegimen 2697 2719	Gemcitabine + Abraxane
A57	TreatmentContinuityVal T340 continuing
A58	TreatmentTypeVal T340 maintenance
A59	TreatmentIntentVal T340 palliative
T341	MedicationRegimen 2739 2761	Gemcitabine + Abraxane
A60	TreatmentContinuityVal T341 continuing
A61	TreatmentTypeVal T341 maintenance
A62	TreatmentIntentVal T341 palliative
T342	MedicationRegimen 2780 2802	Gemcitabine + Abraxane
A63	TreatmentContinuityVal T342 continuing
A64	TreatmentTypeVal T342 maintenance
A65	TreatmentIntentVal T342 palliative
T343	MedicationRegimen 2822 2844	Gemcitabine + Abraxane
A66	TreatmentContinuityVal T343 continuing
A67	TreatmentTypeVal T343 maintenance
A68	TreatmentIntentVal T343 palliative
T344	MedicationRegimen 2862 2884	Gemcitabine + Abraxane
A69	TreatmentContinuityVal T344 continuing
A70	TreatmentTypeVal T344 maintenance
A71	TreatmentIntentVal T344 palliative
T345	Symptom 3024 3030	chills
A72	NegationModalityVal T345 negated
T346	Symptom 3032 3043	diaphoresis
A73	NegationModalityVal T346 negated
T347	Symptom 3045 3050	fever
A74	NegationModalityVal T347 negated
T348	Symptom 3052 3059	malaise
A75	NegationModalityVal T348 negated
T349	Symptom 3059 3067	/fatigue
A76	NegationModalityVal T349 negated
T350	Symptom 3072 3083	weight loss
A77	NegationModalityVal T350 negated
T351	Symptom 3106 3116	nosebleeds
A78	NegationModalityVal T351 negated
T352	MedicationRegimen 1854 1874	Liposomal irinotecan
A79	TreatmentContinuityVal T352 finished
A80	TreatmentIntentVal T352 palliative
A81	NegationModalityVal T98 negated
A82	NegationModalityVal T99 negated
A83	NegationModalityVal T100 negated
A84	NegationModalityVal T101 negated
A85	NegationModalityVal T102 negated
A86	NegationModalityVal T103 affirmed
A87	NegationModalityVal T104 negated
A88	NegationModalityVal T105 negated
A89	NegationModalityVal T106 negated
A90	NegationModalityVal T107 negated
A91	NegationModalityVal T108 negated
A92	NegationModalityVal T109 negated
A93	NegationModalityVal T110 negated
A94	NegationModalityVal T111 negated
A95	NegationModalityVal T112 negated
A96	NegationModalityVal T113 negated
A97	NegationModalityVal T115 negated
A98	NegationModalityVal T116 negated
A99	NegationModalityVal T117 negated
A100	NegationModalityVal T118 negated
A101	NegationModalityVal T119 negated
A102	NegationModalityVal T120 negated
A103	NegationModalityVal T121 negated
T3	Drugs 3784 3799	substance abuse
A104	NegationModalityVal T3 negated
T353	Symptom 3839 3846	nervous
A105	NegationModalityVal T353 negated
A106	NegationModalityVal T122 negated
A107	NegationModalityVal T123 negated
A108	ChronicVal T125 chronic
A109	ContinuityVal T125 stable
A110	ChronicVal T130 chronic
A111	ContinuityVal T130 stable
A112	ChronicVal T132 chronic
A113	ContinuityVal T132 stable
A114	ChronicVal T134 chronic
A115	ContinuityVal T134 stable
A117	ContinuityVal T126 unclear
A116	IntentVal T130 others
A118	TreatmentTypeVal T130 others
A119	TreatmentCategory T130 Others
R13	TestOrProcedureConductedForProblem Test:T130 Prob:T134	
A120	ChronicVal T131 chronic
A121	ContinuityVal T131 stable
A122	IntentVal T131 others
A123	TreatmentTypeVal T131 others
A124	TreatmentCategory T131 Others
R14	TestOrProcedureConductedForProblem Test:T131 Prob:T134	
T354	ProcedureName 4349 4366	BREAST LUMPECTOMY
A125	IntentVal T354 DiagnosisAndTreatment
A126	TreatmentTypeVal T354 local
A127	TreatmentCategory T354 AntiNeoPlastics
A128	IsTumorRemaining T354 unclear
A129	IntentVal T136 others
A130	IntentVal T137 others
A131	TreatmentCategory T137 Supportive
T355	ProcedureName 4478 4515	IR PERCUTANEOUS CHOLECYSTOSTOMY DRAIN
A132	IntentVal T355 others
A133	TreatmentTypeVal T355 others
A134	TreatmentCategory T355 Others
A135	IntentVal T140 others
A136	TreatmentTypeVal T140 others
A137	TreatmentCategory T140 Others
A138	IntentVal T141 others
A139	IntentVal T142 others
T356	ProcedureName 4852 4863	LUNG BIOPSY
A140	IntentVal T144 others
T357	Datetime 4041 4051	02/26/2018
T358	Datetime 4377 4381	2007
T359	Datetime 4408 4412	2014
T360	Datetime 4414 4418	2015
T361	Datetime 4463 4473	02/28/2018
T362	Datetime 4249 4259	11/14/2016
T363	Datetime 4540 4550	02/26/2018
T364	Datetime 4615 4625	02/26/2018
T365	Datetime 4725 4735	01/30/2018
T366	Datetime 4799 4809	01/30/2018
T367	Datetime 4865 4869	2016
A141	IntentVal T127 others
T368	Laterality 4367 4376	Bilateral
R15	HappensAtOnDuring Arg1:T357 Arg2:T127	
A142	ChronicVal T133 non-chronic
A143	ContinuityVal T133 stopped
R16	HappensAtOnDuring Arg1:T362 Arg2:T133	
R17	HappensAtOnDuring Arg1:T358 Arg2:T354	
R18	HappensAtOnDuring Arg1:T359 Arg2:T136	
R19	HappensAtOnDuring Arg1:T360 Arg2:T136	
R20	HappensAtOnDuring Arg1:T361 Arg2:T137	
R21	HappensAtOnDuring Arg1:T363 Arg2:T355	
R22	HappensAtOnDuring Arg1:T364 Arg2:T140	
T369	Site 4349 4355	BREAST
R23	LateralityOfSite Arg1:T368 Arg2:T369	
R24	HappensAtOnDuring Arg1:T141 Arg2:T365	
R25	HappensAtOnDuring Arg1:T142 Arg2:T366	
R26	HappensAtOnDuring Arg1:T356 Arg2:T367	
A144	ChronicVal T114 non-chronic
A145	ContinuityVal T114 worsening
R27	ConditionOrTreatmentCausesProblem Treatment:T342 Prob:T114	
T370	Age 103 105	71
T371	MedicationName 764 784	olanzapine (Zyprexa)
A146	TreatmentContinuityVal T371 unclear
A147	TreatmentTypeVal T371 others
A148	TreatmentIntentVal T371 others
A149	TreatmentCategory T371 Supportive
R28	TreatmentAdministeredForProblem Treatment:T371 Prob:T327	
R29	TreatmentAdministeredForProblem Treatment:T371 Prob:T326	
T372	ProcedureName 788 791;793 805	EUS Celiac block
A150	IntentVal T372 others
A151	TreatmentCategory T372 Supportive
T373	Datetime 806 818	October 2016
R30	HappensAtOnDuring Arg1:T373 Arg2:T372	
R31	HappensAtOnDuring Arg1:T299 Arg2:T316	
A152	IntentVal T36 TreatmentAssessment
R32	HappensAtOnDuring Arg1:T300 Arg2:T36	
T374	RadPathResult 901 927	slight increase in primary
A153	RadPathResultVal T374 Progression
R33	ResultOfTest Desc:T374 Test:T36	
T375	DiagnosticLabTest 933 940	CA 19-9
A154	IntentVal T375 TreatmentAssessment
T376	LabTestResult 945 953	dropping
A155	RadPathResultVal T376 TreatmentResponse
A156	LabTestResultVal T376 abnormal
R34	ResultOfTest Desc:T376 Test:T375	
T377	Cycles 969 971	19
R35	TreatmentDesc Therapy:T377 Desc:T317	
R36	HappensAtOnDuring Arg1:T301 Arg2:T317	
R37	TreatmentDesc Therapy:T328 Desc:T319	
R38	HappensAtOnDuring Arg1:T302 Arg2:T318	
T378	RadPathResult 1676 1690	stable disease
A157	RadPathResultVal T378 DiseaseStability
R39	ResultOfTest Desc:T378 Test:T331	
A158	IntentVal T58 TreatmentAssessment
T379	LabTestResult 1733 1747	upwards by 30%
A159	LabTestResultVal T379 abnormal
R40	ResultOfTest Desc:T379 Test:T58	
T380	DiseaseState 1702 1747	umor markers had been trending upwards by 30%
A160	NegationModalityVal T380 uncertain_in_present
T381	Symptom 1791 1797	nausea
A161	IsPresentOnFirstCancerDiagnosis T381 no
A162	IsCausedByDiagnosedCancer T381 unclear
A163	ChronicVal T381 non-chronic
A164	ContinuityVal T381 worsening
T382	Symptom 1798 1806	vomiting
A165	IsPresentOnFirstCancerDiagnosis T382 no
A166	IsCausedByDiagnosedCancer T382 unclear
A167	ChronicVal T382 non-chronic
A168	ContinuityVal T382 worsening
T383	DiseaseState 1833 1852	disease progression
A169	NegationModalityVal T383 uncertain_in_present
T384	GenomicTest 2011 2021	BRCA2 gene
A170	GenomicTestType T384 Unclear
T385	GenomicTestResult 1964 1982;1985 1997	variant of unknown significance
A171	GenomicTestType T385 Unclear
R41	ResultOfTest Desc:T385 Test:T384	
T386	ClinicalTrial 2105 2132	nab-paclitaxel + CORT125134
A172	NegationModalityVal T386 hypothetical_in_future
A173	ChronicVal T66 non-chronic
A174	ContinuityVal T66 new
T387	ClinicalCondition 2246 2272	gastric outlet obstruction
A175	ChronicVal T387 non-chronic
A176	ContinuityVal T387 new
T388	ProcedureName 2274 2278	ERCP
A177	IntentVal T388 others
A178	TreatmentTypeVal T388 others
A179	TreatmentCategory T388 Others
R42	TestOrProcedureConductedForProblem Test:T388 Prob:T66	
R43	TestOrProcedureConductedForProblem Test:T388 Prob:T387	
A180	ChronicVal T69 non-chronic
A181	ContinuityVal T69 new
A182	IntentVal T71 others
A183	TreatmentTypeVal T71 others
A184	TreatmentCategory T71 Others
A185	IntentVal T72 others
A186	TreatmentTypeVal T72 others
A187	TreatmentCategory T72 Others
T389	Datetime 2439 2450	February 27
R44	HappensAtOnDuring Arg1:T72 Arg2:T389	
T390	ProcedureName 2465 2479	duodenal stent
A188	IntentVal T390 others
A189	TreatmentTypeVal T390 others
A190	TreatmentCategory T390 Others
T391	Site 2509 2523	gastric antrum
T392	Site 2552 2579	2nd portion of the duodenum
R45	SiteOf Arg1:T391 Arg2:T390	
R46	SiteOf Arg1:T392 Arg2:T390	
T393	Datetime 2583 2594	February 29
R47	HappensAtOnDuring Arg1:T393 Arg2:T390	
R48	TreatmentDesc Therapy:T332 Desc:T338	
T394	Cycles 2650 2655	C1D15
T395	Datetime 2599 2607	03/19/18
T396	Datetime 2639 2647	04/02/18
T397	Datetime 2682 2690	04/17/18
T398	Datetime 2723 2731	05/01/18
T399	Datetime 2765 2773	05/20/18
T400	Datetime 2806 2814	06/03/18
T401	Datetime 2847 2855	06/17/18
R49	BeginsOnOrAt Arg1:T395 Arg2:T338	
R50	HappensAtOnDuring Arg1:T396 Arg2:T339	
R51	TreatmentDesc Therapy:T394 Desc:T339	
R52	HappensAtOnDuring Arg1:T397 Arg2:T340	
R53	TreatmentDesc Therapy:T333 Desc:T340	
R54	HappensAtOnDuring Arg1:T398 Arg2:T341	
R55	TreatmentDesc Therapy:T334 Desc:T341	
R56	HappensAtOnDuring Arg1:T399 Arg2:T342	
R57	TreatmentDesc Therapy:T335 Desc:T342	
R58	HappensAtOnDuring Arg1:T400 Arg2:T343	
R59	TreatmentDesc Therapy:T336 Desc:T343	
R60	HappensAtOnDuring Arg1:T401 Arg2:T344	
R61	TreatmentDesc Therapy:T337 Desc:T344	
T402	Symptom 2917 2927	neuropathy
A191	IsPresentOnFirstCancerDiagnosis T402 no
A192	IsCausedByDiagnosedCancer T402 no
A193	ChronicVal T402 non-chronic
A194	ContinuityVal T402 worsening
R62	ConditionOrTreatmentCausesProblem Treatment:T344 Prob:T402	
T403	Symptom 2939 2947	abd pain
A195	IsPresentOnFirstCancerDiagnosis T403 no
A196	IsCausedByDiagnosedCancer T403 yes
A197	ChronicVal T403 non-chronic
A198	ContinuityVal T403 improving
T404	Symptom 2951 2967	Trouble sleeping
A199	IsPresentOnFirstCancerDiagnosis T404 no
A200	IsCausedByDiagnosedCancer T404 unclear
A201	ContinuityVal T404 unclear
T405	MedicationName 4932 4941	albuterol
A202	TreatmentContinuityVal T405 continuing
A203	TreatmentTypeVal T405 others
A204	TreatmentIntentVal T405 others
A205	TreatmentCategory T405 Others
A206	TreatmentContinuityVal T147 continuing
A207	TreatmentTypeVal T147 others
A208	TreatmentIntentVal T147 others
A209	TreatmentCategory T147 Others
A210	TreatmentContinuityVal T148 continuing
A211	TreatmentTypeVal T148 others
A212	TreatmentIntentVal T148 others
A213	TreatmentCategory T148 Others
A214	TreatmentContinuityVal T150 continuing
A215	TreatmentTypeVal T150 others
A216	TreatmentIntentVal T150 others
A217	TreatmentCategory T150 Others
A218	TreatmentContinuityVal T151 continuing
A219	TreatmentTypeVal T151 others
A220	TreatmentIntentVal T151 others
A221	TreatmentCategory T151 Supportive
A222	TreatmentContinuityVal T153 continuing
A223	TreatmentTypeVal T153 others
A224	TreatmentIntentVal T153 others
A225	TreatmentCategory T153 Supportive
A226	TreatmentContinuityVal T156 continuing
A227	TreatmentTypeVal T156 others
A228	TreatmentIntentVal T156 others
A229	TreatmentCategory T156 Supportive
A230	TreatmentContinuityVal T158 continuing
A231	TreatmentTypeVal T158 others
A232	TreatmentIntentVal T158 others
A233	TreatmentCategory T158 Others
A234	TreatmentContinuityVal T159 continuing
A235	TreatmentTypeVal T159 others
A236	TreatmentIntentVal T159 others
A237	TreatmentCategory T159 Supportive
A238	TreatmentContinuityVal T163 continuing
A239	TreatmentTypeVal T163 others
A240	TreatmentIntentVal T163 others
A241	TreatmentCategory T163 Others
A242	TreatmentContinuityVal T164 continuing
A243	TreatmentTypeVal T164 others
A244	TreatmentIntentVal T164 others
A245	TreatmentCategory T164 Supportive
A246	TreatmentContinuityVal T166 continuing
A247	TreatmentTypeVal T166 others
A248	TreatmentIntentVal T166 others
A249	TreatmentCategory T166 Supportive
A250	TreatmentContinuityVal T167 continuing
A251	TreatmentTypeVal T167 others
A252	TreatmentIntentVal T167 others
A253	TreatmentCategory T167 Others
T168	MedicationName 6423 6436	heparin flush
A254	TreatmentContinuityVal T168 unclear
A255	TreatmentTypeVal T168 others
A256	TreatmentIntentVal T168 others
A257	TreatmentCategory T168 Others
T406	TreatmentDosage 5424 5446;5473 5480	24,000-76,000 -120,000 3-4 cap
T407	TreatmentDosage 5554 5558	1 mg
T408	TreatmentDosage 5316 5331	100-50 mcg/dose
T409	TreatmentDosage 5154 5166	2.5-0.025 mg
T411	TreatmentDosage 5085 5090	10 mg
R63	TreatmentDesc Therapy:T406 Desc:T151	
R64	TreatmentDesc Therapy:T408 Desc:T150	
R65	TreatmentDesc Therapy:T407 Desc:T153	
T412	TreatmentDosage 5684 5689;5702 5707	10 mg 1 tab
T414	TreatmentDosage 5891 5895	5 mg
T415	TreatmentDosage 6065 6070	0.1 %
T417	TreatmentDosage 6275 6281	150 mg
T418	TreatmentDosage 6467 6489	500 Units Inject 5 mLs
T413	TreatmentDosage 5825 5830	15 mg
T419	TreatmentDosage 5581 5585	1 mg
T416	TreatmentDosage 6168 6175	5-10 mg
T420	TreatmentDosage 4942 4958	90 mcg/actuation
R66	TreatmentDesc Therapy:T405 Desc:T420	
R67	TreatmentDesc Therapy:T147 Desc:T411	
R68	TreatmentDesc Therapy:T148 Desc:T409	
T410	Symptom 5197 5217	loose bowel movement
A258	NegationModalityVal T410 hypothetical_in_future
R69	TreatmentAdministeredForProblem Treatment:T148 Prob:T410	
T421	Symptom 5256 5264	DIARRHEA
A259	NegationModalityVal T421 hypothetical_in_future
R70	TreatmentAdministeredForProblem Treatment:T148 Prob:T421	
T422	Symptom 5635 5641	nausea
A260	NegationModalityVal T422 hypothetical_in_future
T423	Symptom 5642 5650	vomiting
A261	NegationModalityVal T423 hypothetical_in_future
R72	TreatmentAdministeredForProblem Treatment:T153 Prob:T422	
R73	TreatmentAdministeredForProblem Treatment:T153 Prob:T423	
A262	NegationModalityVal T157 hypothetical_in_future
R74	TreatmentDesc Therapy:T156 Desc:T412	
R75	TreatmentAdministeredForProblem Treatment:T156 Prob:T157	
T424	MaritalStatus 7283 7290	Married
A263	NegationModalityVal T424 affirmed
A264	IsStoppedOrContinuing T424 continuing
T425	Tobacco 7750 7762	Never Smoker
A265	NegationModalityVal T425 negated
T426	Alcohol 7846 7849	Yes
A266	NegationModalityVal T426 affirmed
A267	IsStoppedOrContinuing T426 continuing
T427	ConsumptionQuantity 7863 7875	1x per month
R76	ConsumptionQuantityRel Arg1:T426 Arg2:T427	
T428	Drugs 7907 7916	Marijuana
A268	IsStoppedOrContinuing T428 continuing
T429	Age 11084 11086	71
T430	ClinicalCondition 11115 11133	pancreatic  cancer
A269	ChronicVal T430 chronic
A270	ContinuityVal T430 stable
T431	ClinicalCondition 11179 11196	pancreatic cancer
A271	ChronicVal T431 chronic
A272	ContinuityVal T431 stable
T432	Metastasis 11104 11114	metastatic
A273	EpisodeDescription T432 FirstOccurrence
T433	Metastasis 11168 11178	Metastatic
A274	EpisodeDescription T433 FirstOccurrence
R77	TumorDesc TumorDetails:T432 Desc:T430	
R78	TumorDesc TumorDetails:T433 Desc:T431	
T434	MedicationRegimen 11212 11224	gem abraxane
A275	TreatmentContinuityVal T434 continuing
T435	MedicationName 11278 11286	abraxane
A276	TreatmentContinuityVal T435 continuing
A277	TreatmentTypeVal T435 maintenance
A278	TreatmentIntentVal T435 palliative
A279	TreatmentCategory T435 AntiNeoPlastics
T436	Symptom 11249 11259	neuropathy
A280	IsPresentOnFirstCancerDiagnosis T436 no
A281	IsCausedByDiagnosedCancer T436 no
A282	ChronicVal T436 non-chronic
A283	ContinuityVal T436 worsening
R79	ConditionOrTreatmentCausesProblem Treatment:T435 Prob:T436	
A284	DiseaseStateVal T271 stability
A285	IsPresentOnFirstCancerDiagnosis T274 no
A286	IsCausedByDiagnosedCancer T274 no
A287	ChronicVal T274 non-chronic
A288	ContinuityVal T274 worsening
T437	Duration 11318 11325	2 weeks
T438	Datetime 11354 11366	September 22
A289	IntentVal T275 TreatmentAssessment
A290	NegationModalityVal T275 planned_in_future
R80	HappensAtOnDuring Arg1:T275 Arg2:T438	
A291	NegationModalityVal T276 affirmed
A292	TreatmentContinuityVal T276 started
A293	TreatmentTypeVal T276 others
A294	TreatmentIntentVal T276 others
A295	TreatmentCategory T276 Supportive
T439	ClinicalCondition 11371 11381	dperession
A296	ChronicVal T439 non-chronic
A297	ContinuityVal T439 new
R81	TreatmentAdministeredForProblem Treatment:T276 Prob:T439	
A298	IsPresentOnFirstCancerDiagnosis T277 no
A299	IsCausedByDiagnosedCancer T277 unclear
A300	ChronicVal T277 non-chronic
A301	ContinuityVal T277 stable
A302	IsPresentOnFirstCancerDiagnosis T278 no
A303	IsCausedByDiagnosedCancer T278 unclear
A304	ChronicVal T278 non-chronic
A305	ContinuityVal T278 stable
T440	ClinicalCondition 11434 11437	GOO
A306	ChronicVal T440 non-chronic
A307	ContinuityVal T440 stopped
T441	ProcedureName 11438 11445	stented
A308	IntentVal T441 others
A309	TreatmentTypeVal T441 others
A310	TreatmentCategory T441 Others
R82	TestOrProcedureConductedForProblem Test:T441 Prob:T440	
R83	ConditionOrTreatmentCausesProblem Treatment:T440 Prob:T278	
R84	ConditionOrTreatmentCausesProblem Treatment:T440 Prob:T277	
A311	IsPresentOnFirstCancerDiagnosis T280 no
A312	IsCausedByDiagnosedCancer T280 no
A313	ChronicVal T280 non-chronic
A314	ContinuityVal T280 worsening
R85	TreatmentDesc Therapy:T158 Desc:T413	
R86	TreatmentDesc Therapy:T159 Desc:T414	
T442	Symptom 6032 6038	NAUSEA
A315	NegationModalityVal T442 hypothetical_in_future
R87	TreatmentAdministeredForProblem Treatment:T159 Prob:T442	
R88	TreatmentDesc Therapy:T163 Desc:T415	
R89	TreatmentDesc Therapy:T164 Desc:T416	
A316	NegationModalityVal T165 hypothetical_in_future
R90	TreatmentAdministeredForProblem Treatment:T164 Prob:T165	
R91	TreatmentDesc Therapy:T166 Desc:T417	
A317	DiseaseStateVal T325 progression-others
A318	DiseaseStateVal T380 progression-others
T443	Datetime 2026 2034	01/21/18
R92	HappensAtOnDuring Arg1:T443 Arg2:T386	
R93	HappensAtOnDuring Arg1:T303 Arg2:T321	
R94	TreatmentDesc Therapy:T312 Desc:T321	
R95	HappensAtOnDuring Arg1:T304 Arg2:T329	
A319	ChronicVal T43 non-chronic
A320	ContinuityVal T43 new
R96	HappensAtOnDuring Arg1:T300 Arg2:T375	
R97	ConditionOrTreatmentCausesProblem Treatment:T318 Prob:T43	
T444	Datetime 1114 1118	2017
T445	DiseaseState 1149 1169	interval progression
A321	NegationModalityVal T445 affirmed
A322	DiseaseStateVal T445 progression-others
R98	TestOrProcedureReveals Test:T329 Desc:T445	
T446	Metastasis 1191 1198	disease
A323	NegationModalityVal T446 negated
T447	Site 1177 1182	lungs
T448	Site 1206 1211	liver
R99	SiteOf Arg1:T448 Arg2:T446	
R100	HappensAtOnDuring Arg1:T305 Arg2:T319	
R101	TreatmentDesc Therapy:T328 Desc:T318	
R102	SiteOf Arg1:T447 Arg2:T445	
R103	HappensAtOnDuring Arg1:T43 Arg2:T444	
R104	HappensAtOnDuring Arg1:T306 Arg2:T330	
R105	HappensAtOnDuring Arg1:T308 Arg2:T320	
T449	TreatmentDoseModification 1070 1075	66.7%
R106	TreatmentDesc Therapy:T297 Desc:T320	
R107	TreatmentDesc Therapy:T449 Desc:T321	
R108	HappensAtOnDuring Arg1:T309 Arg2:T322	
R109	EndsOnOrAt Arg1:T310 Arg2:T323	
R110	TreatmentDesc Therapy:T298 Desc:T323	
R111	HappensAtOnDuring Arg1:T311 Arg2:T331	
T450	TreatmentDoseModification 11262 11277	Further reduced
R112	TreatmentDesc Therapy:T450 Desc:T435	
T451	DiseaseState 1294 1308	stable disease
A324	DiseaseStateVal T451 stability
R113	TestOrProcedureReveals Test:T330 Desc:T451	
A325	TreatmentTypeVal T51 others
A326	TreatmentCategory T51 Others
T452	ProcedureName 1438 1474	placement of midline venous catheter
A327	TreatmentTypeVal T452 others
A328	TreatmentCategory T452 Others
R114	HappensAtOnDuring Arg1:T307 Arg2:T51	
R115	HappensAtOnDuring Arg1:T307 Arg2:T452	
T453	ClinicalCondition 1340 1361	catheter-related clot
A329	ChronicVal T453 non-chronic
A330	ContinuityVal T453 worsening
T454	Site 1375 1378	SVC
T455	Laterality 1369 1374	right
R116	LateralityOfSite Arg1:T455 Arg2:T454	
R117	SiteOf Arg1:T454 Arg2:T453	
R118	TestOrProcedureReveals Test:T329 Desc:T453	
R119	InclusionCriteriaFor Arg1:T385 Arg2:T386	
R120	TestOrProcedureReveals Test:T388 Desc:T69	
R122	NotUndergoneBecauseOf Arg1:T71 Reason:T69	
R71	TreatmentDesc Therapy:T153 Desc:T419	
R121	TreatmentDesc Therapy:T418 Desc:T168	
T456	SectionSkip 6569 6761	Allergies/Contraindications   Allergen Reactions    Levofloxacin Rash    Shellfish Containing Products Hives and Itching    Alendronate Sodium Rash    Anastrozole Rash    Terbinafine Rash
A331	SectionSkipType T456 allergies
A332	SectionSkipType T10 laboratory
A334	SectionSkipType T11 physical_exam
A335	SectionSkipType T13 laboratory
T12	SectionSkip 9322 9827;9830 10423	LABORATORY RESULTS  I have reviewed the following labs in clinic today and discussed them with the patient.  Lab Results   Component Value Date    WBC Count 5.3 08/12/2018    Neutrophil Absolute Count 3.56 08/12/2018    Hemoglobin 10.1 (L) 08/12/2018    Hematocrit 32.1 (L) 08/12/2018    Platelet Count 159 08/12/2018     Lab Results   Component Value Date    Creatinine 0.51 08/12/2018    Sodium, Serum / Plasma 136 07/29/2018    Potassium, Serum / Plasma 4.2 07/29/2018    Calcium, total, Serum / Plasma 8.3 (L) 07/29/2018     Lab Results   Component Value Date    Bilirubin, Total 0.4 08/12/2018    Alkaline Phosphatase 61 08/12/2018    Aspartate transaminase 28 08/12/2018    Alanine transaminase 25 08/12/2018    Albumin, Serum / Plasma 3.1 (L) 07/29/2018    Int'l Normaliz Ratio 1.1 02/28/2018     Lab Results   Component Value Date    Cancer Antigen 19-9 1,109 (H) 07/15/2018    Cancer Antigen 19-9 2,762 (H) 06/17/2018    Cancer Antigen 19-9 3,525 (H) 05/20/2018    Carcinoembryonic Antigen 3.0 08/04/2015    Carcinoembryonic Antigen 2.7 06/07/2015    Carcinoembryonic Antigen 2.5 04/04/2015
A333	SectionSkipType T12 laboratory
T15	GenomicTest 10439 10443	BRCA
A336	NegationModalityVal T15 affirmed
A337	GenomicTestType T15 Germline
T16	GenomicTestResult 10444 10475	variant of unknown significance
A338	GenomicTestType T16 Somatic
R123	ResultOfTest Desc:T16 Test:T15	
A339	NegationModalityVal T255 affirmed
A340	ExperiencerVal T255 family
T457	ClinicalCondition 10547 10553;10569 10575	breast cancer
A341	ChronicVal T457 chronic
A342	ExperiencerVal T457 patient
T458	Datetime 11401 11406	today
R124	BeginsOnOrAt Arg1:T276 Arg2:T458	
T459	ClinicalCondition 10558 10575	pancreatic cancer
A343	ChronicVal T459 chronic
A344	GenomicTestType T257 Somatic
T460	GenomicTest 10588 10594	CDKN2a
A345	GenomicTestType T460 Somatic
T461	GenomicTest 10599 10602	APC
A346	GenomicTestType T461 Somatic
T462	GenomicTestResult 10603 10612	mutations
A347	NegationModalityVal T462 affirmed
A348	GenomicTestType T462 Somatic
R125	ResultOfTest Desc:T462 Test:T461	
R126	ResultOfTest Desc:T462 Test:T460	
R127	ResultOfTest Desc:T462 Test:T257	
T463	SectionSkip 10626 11054	RADIOGRAPHIC RESULTS   CT Chest abd pelvis 07/14/2018:  Unchanged size and number of bilateral pulmonary nodules consistent with treated metastases.  Compared to 05/09/2018, interval decrease in size of hypoattenuating/hypoenhancing proximal pancreatic body mass with interval decrease in associated infiltrative soft tissue. No significant interval change in associated vascular encasement and occlusion as characterized above.
A349	SectionSkipType T463 radiology_report
T464	ClinicalCondition 6823 6837	Stomach cancer
A350	ExperiencerVal T464 family
T465	Age 6846 6848	71
R128	BeginsOnOrAt Arg1:T464 Arg2:T465	
T466	ClinicalCondition 6853 6865	Colon cancer
A351	ExperiencerVal T466 family
T467	ClinicalCondition 6881 6894	Rectal cancer
A352	ExperiencerVal T467 family
T468	ClinicalCondition 6910 6923	Breast cancer
A353	ExperiencerVal T468 family
T469	ClinicalCondition 6946 6952	Cancer
A354	ExperiencerVal T469 family
T470	ClinicalCondition 6974 6987	Breast cancer
A355	ExperiencerVal T470 family
T471	ClinicalCondition 7015 7027	Brain cancer
A356	ExperiencerVal T471 family
T472	ClinicalCondition 7070 7083	Breast cancer
A357	ExperiencerVal T472 family
T473	ClinicalCondition 7104 7110	Cancer
A358	ExperiencerVal T473 family
T474	ClinicalCondition 7131 7144	Breast cancer
A359	ExperiencerVal T474 family
T475	Age 6874 6876	59
T476	Age 6903 6905	64
T477	Age 6939 6941	45
R129	BeginsOnOrAt Arg1:T466 Arg2:T475	
R130	BeginsOnOrAt Arg1:T467 Arg2:T476	
R131	BeginsOnOrAt Arg1:T468 Arg2:T477	
T478	Age 7155 7157	42
R132	BeginsOnOrAt Arg1:T474 Arg2:T478	
A360	DiseaseStateVal T383 progression-others
T479	hpi_start 0 6	REASON
T480	hpi_end 2959 2968	sleeping.
T481	ap_start 11058 11068	Assessment
T482	ap_end 11512 11517	check
T483	hpi_start 10428 10437	Molecular
T484	hpi_end 10616 10621	well.
R133	HappensBefore Arg1:T314 Arg2:T373	
R134	HappensAtOnDuring Arg1:T298 Arg2:T310	
R135	EndsOnOrAt Arg1:T352 Arg2:T310	
R136	EndsOnOrAt Arg1:T309 Arg2:T321	
R137	HappensAtOnDuring Arg1:T395 Arg2:T332	
R138	HappensAtOnDuring Arg1:T396 Arg2:T394	
R139	HappensAtOnDuring Arg1:T397 Arg2:T333	
R140	HappensAtOnDuring Arg1:T398 Arg2:T334	
R141	HappensAtOnDuring Arg1:T399 Arg2:T335	
R142	HappensAtOnDuring Arg1:T400 Arg2:T336	
R143	HappensAtOnDuring Arg1:T401 Arg2:T337	
T485	SectionSkip 4896 5926;5929 6560	Current Medications       Dosage    albuterol 90 mcg/actuation metered dose inhaler Inhale 1-2 puffs into the lungs every 6 (six) hours as needed.     cetirizine (ZYRTEC) 10 mg tablet Take 10 mg by mouth daily as needed.     diphenoxylate-atropine (LOMOTIL) 2.5-0.025 mg tablet Take 2 tabs after each loose bowel movement. You can take up to 8 tabs a day. FOR DIARRHEA.    fluticasone propion-salmeterol (ADVAIR DISKUS) 100-50 mcg/dose diskus inhaler Inhale 1 puff into the lungs Twice a day.    lipase-protease-amylase (CREON) 24,000-76,000 -120,000 unit CAPDREC capsule take 3-4 caps with each meal and April 23 caps with each snack.    LORazepam (ATIVAN) 1 mg tablet Take 1 tablet (1 mg total) by mouth every 8 (eight) hours as needed (nausea/vomiting).    metoclopramide HCl (REGLAN) 10 mg tablet Take 1 tab 30 minutes prior to every meal. Take 3 times a day. For NAUSEA.    mirtazapine (REMERON) 15 mg tablet Take 1 tablet (15 mg total) by mouth nightly at bedtime.    OLANZapine (ZYPREXA) 5 mg tablet Take 1 or 2 tabs on the day of chemotherapy followed by 1 or 2 tabs once daily for 3 days following chemotherapy infusion. FOR NAUSEA.    olopatadine (PATANOL) 0.1 % ophthalmic solution Apply 1 drop to eye.    oxyCODONE (ROXICODONE) 5 mg tablet Take 1-2 tablets (5-10 mg total) by mouth every 4 (four) hours as needed for Pain.    ranitidine (ZANTAC) 150 mg tablet Take 150 mg by mouth Twice a day.    TRIAMCINOLONE ACETONIDE (NASACORT NASAL) by Nasal route daily as needed.       Hospital Medications       Dosage    heparin flush 100 unit/mL injection syringe 500 Units Inject 5 mLs (500 Units total) into the vein As needed (line flush after each use).
A361	SectionSkipType T485 medications
